Cargando…

Left ventricular mass predicts cardiac reverse remodelling in patients treated with empagliflozin

BACKGROUND: The cardiovascular (CV) benefits of sodium-glucose transport protein 2 inhibitors have been attributed, in part, to cardiac reverse remodelling. The EMPA-HEART CardioLink-6 study reported that sodium-glucose cotransporter-2 inhibition for 6 months with empagliflozin was associated with a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puar, Pankaj, Hibino, Makoto, Mazer, C. David, Yan, Andrew T., Pandey, Arjun K., Quan, Adrian, Teoh, Hwee, Hess, David A., Verma, Raj, Connelly, Kim A., Verma, Subodh
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303338/ https://www.ncbi.nlm.nih.gov/pubmed/37380983 http://dx.doi.org/10.1186/s12933-023-01849-w

Ejemplares similares

Impact of diabetes duration on left ventricular mass regression with empagliflozin
por: Moroney, Michael, et al.
Publicado: (2023)

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
por: Verma, Raj, et al.
Publicado: (2023)

Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial
por: Barbour, William, et al.
Publicado: (2023)

Stage‐based approach to predict left ventricular reverse remodeling after mitral repair
por: Hibino, Makoto, et al.
Publicado: (2022)

IGFBP7 and left ventricular mass regression: a sub‐analysis of the EMPA‐HEART CardioLink‐6 randomized clinical trial
por: Puar, Pankaj, et al.
Publicado: (2023)

The Impact of Statins on Postdischarge Atrial Fibrillation After Cardiac Surgery: Secondary Analysis from a Randomized Trial
por: Hibino, Makoto, et al.
Publicado: (2022)

SGLT2 inhibitors and cardiac remodelling: a systematic review and meta‐analysis of randomized cardiac magnetic resonance imaging trials
por: Dhingra, Nitish K., et al.
Publicado: (2021)

Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes
por: Sarak, Bradley, et al.
Publicado: (2021)

Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis
por: Garg, Vinay, et al.
Publicado: (2020)

Predictors of mitral valve haemodynamics after mitral valve repair for degenerative mitral regurgitation
por: Rumman, Rawan K, et al.
Publicado: (2023)

Sodium‐glucose cotransporter 2 inhibitors in heart failure with reduced or preserved ejection fraction: a meta‐analysis
por: Pandey, Arjun K., et al.
Publicado: (2022)

Circulating Pro-Vascular Progenitor Cell Depletion During Type 2 Diabetes: Translational Insights Into the Prevention of Ischemic Complications in Diabetes
por: Terenzi, Daniella C., et al.
Publicado: (2018)

Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
por: Verma, Subodh, et al.
Publicado: (2018)

Role of Endothelium in Doxorubicin-Induced Cardiomyopathy
por: Luu, Albert Z., et al.
Publicado: (2018)

Endothelial cell control of thrombosis
por: Yau, Jonathan W., et al.
Publicado: (2015)

Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia
por: Sherman, Stephen E., et al.
Publicado: (2018)

Vascular Risk Reduction in Obesity through Reduced Granulocyte Burden and Improved Angiogenic Monocyte Content following Bariatric Surgery
por: Hess, David A., et al.
Publicado: (2020)

Attenuation of Adverse Postinfarction Left Ventricular Remodeling with Empagliflozin Enhances Mitochondria-Linked Cellular Energetics and Mitochondrial Biogenesis
por: Song, Yang, et al.
Publicado: (2021)

Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
por: Verma, Subodh, et al.
Publicado: (2018)

Surgical Ventricular Restoration to Reverse Left Ventricular Remodeling
por: Castelvecchio, Serenella, et al.
Publicado: (2010)

Isolation and characterization of circulating pro-vascular progenitor cell subsets from human whole blood samples
por: Terenzi, Daniella C., et al.
Publicado: (2021)

Subclinical Valve Thrombosis in Sutureless Bioprosthetic Valves
por: Yanagawa, Bobby, et al.
Publicado: (2017)

Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2020)

Loss of endothelial cell-specific autophagy-related protein 7 exacerbates doxorubicin-induced cardiotoxicity
por: Luu, Albert Z., et al.
Publicado: (2021)

Plasma microRNAs in human left ventricular reverse remodelling
por: Rehan, Rajan, et al.
Publicado: (2020)

The Rare Condition of Left Ventricular Non-Compaction and Reverse Remodeling
por: Bustea, Cristiana, et al.
Publicado: (2023)

Empagliflozin Attenuates Myocardial Sodium and Calcium Dysregulation and Reverses Cardiac Remodeling in Streptozotocin-Induced Diabetic Rats
por: Lee, Ting-I, et al.
Publicado: (2019)

Gender influences left ventricular remodelling in the setting of aortic stenosis but does not appear to impact on reverse remodelling following transcatheter aortic valve implantation
por: Dobson, Laura E, et al.
Publicado: (2015)

Left Ventricular Global Longitudinal Strain as a Predictor for Left Ventricular Reverse Remodeling in Dilated Cardiomyopathy
por: Jung, In Hyun, et al.
Publicado: (2020)

Impact of correction of ischemic mitral valve on left ventricular reverse remodeling
por: Nikolic, A, et al.
Publicado: (2013)

Left ventricular reverse remodelling and its predictors in non‐ischaemic cardiomyopathy
por: Hnat, Tomas, et al.
Publicado: (2022)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
por: Verma, Subodh, et al.
Publicado: (2021)

Investigation of TGFβ1-Induced Long Noncoding RNAs in Endothelial Cells
por: Singh, Krishna K., et al.
Publicado: (2016)

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
por: Filippatos, Gerasimos, et al.
Publicado: (2022)

Effect of Continuous Electrocardiogram Monitoring on Detection of Undiagnosed Atrial Fibrillation After Hospitalization for Cardiac Surgery: A Randomized Clinical Trial
por: Ha, Andrew C. T., et al.
Publicado: (2021)

Preoperative left ventricular ejection fraction and left atrium reverse remodeling after mitral regurgitation surgery
por: Machado, Lucia R, et al.
Publicado: (2014)

Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling
por: Tobita, Takashige, et al.
Publicado: (2018)

MitraClip and left ventricular reverse remodelling: a strain imaging study
por: Papadopoulos, Konstantinos, et al.
Publicado: (2020)

Prediction of Left Ventricular Reverse Remodelling: A Mini Review on Clinical Aspects
por: Chudý, Martin, et al.
Publicado: (2022)

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
por: Byrne, Nikole J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_21s73tg3qvdk36a3jkll0vgkl0